A phase II study of Bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A cytokine Working Group (CWG) study

Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman, Joseph I. Clark, David F. McDermott, Michael B. Atkins, Janice P. Dutcher, Walter J. Urba, Meredith M. Regan, Igor Puzanov, Todd S. Crocenzi, Brendan D. Curti, Ulka N. Vaishampayan, Nancy A. Crosby, Kim A. Margolin, Marc S. Ernstoff*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Overexpression of vascular endothelial growth factor in renal cell carcinoma (RCC) leads to angiogenesis, tumor progression, and inhibition of immune function. We conducted the first phase II study to estimate the efficacy and safety of bevacizumab with highdose interleukin-2 (IL-2) therapy in patients with metastatic RCC. Eligible patients had predominantly clear cell metastatic RCC, measurable disease, a Karnofsky Performance Status of Z80%, and adequate end-organ function. IL-2 (600,000 IU/kg) was infused intravenously every 8 hours (maximum 28 doses) during two 5-day cycles on days 1 and 15 of each 84-day course. Bevacizumab (10mg/kg) was infused intravenously every 2 weeks beginning 2 weeks before initiating IL-2. Fifty of 51 eligible patients from 8 centers were enrolled. Median progression-free survival (PFS) was 11.2 months (90% confidence interval, 5.7-17.7), and 2-year PFS was 18% (90% confidence interval, 8%-27%). Responses included 4 complete (8%) and 11 partial (22%) responses. Toxicities did not exceed those expected from each agent alone. Combining IL-2 plus bevacizumab is feasible, with a response rate and PFS at least as high as reported previously for the single agents. The regimen did not appear to enhance the rate of durable major responses over that of IL-2 alone.

Original languageEnglish (US)
Pages (from-to)490-495
Number of pages6
JournalJournal of Immunotherapy
Volume36
Issue number9
DOIs
StatePublished - Nov 1 2013

Keywords

  • antiangiogenesis
  • immunotherapy
  • interleukin-2
  • renal cell cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of Bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A cytokine Working Group (CWG) study'. Together they form a unique fingerprint.

Cite this